Tenaya Therapeutics (NASDAQ:TNYA) and C4 Therapeutics (NASDAQ:CCCC) Financial SurveyDefense World · 4 days ago
Insmed Appoints Two New Directors to Its BoardPRNewsWire · 5 days ago
Reviewing ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)Defense World · Oct 12, 2026
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual MeetingGlobeNewsWire · Sep 25, 2026
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?Zacks Investment Research · Sep 23, 2026
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual MeetingGlobeNewsWire · Sep 3, 2026C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.23 | -$0.18 | Beat |
| May 12, 2026 | -$0.25 | -$0.20 | Beat |
| Feb 26, 2026 | -$0.31 | -$0.18 | Beat |
| Nov 6, 2025 | -$0.41 | -$0.44 | Miss |
| Aug 7, 2025 | -$0.38 | -$0.37 | Beat |
| May 6, 2025 | -$0.48 | -$0.37 | Beat |